Literature DB >> 11581208

Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes.

C Maihöfner1, U Schlötzer-Schrehardt, H Gühring, H U Zeilhofer, G O Naumann, A Pahl, C Mardin, E R Tamm, K Brune.   

Abstract

PURPOSE: Primary open-angle glaucoma (POAG) is the predominant form of chronic glaucoma, but the underlying pathologic mechanisms are largely unknown. Because prostaglandins (PGs) have been introduced into POAG treatment with remarkable success, this study was undertaken to investigate whether a change in the expression of the PG-synthesizing enzymes cyclooxygenase (COX)-1 and -2 might be involved in the pathogenesis of POAG.
METHODS: Expression of COX-1 and -2 was assessed by confocal laser microscopy, immunohistochemistry, Western blot analysis, and real-time RT-PCR in human eyes with different forms of glaucoma (primary open-angle, angle-closure, congenital juvenile, and steroid-induced), as well as in age-matched control eyes. Additionally, PGE2 was measured in aqueous humor by means of an enzyme-linked immunoassay as a product of COX activity.
RESULTS: In normal eyes, ocular COX-1 and -2 expression were largely confined to the nonpigmented secretory epithelium of the ciliary body. By immunohistochemistry and real-time RT-PCR, COX-2 expression was completely lost in the nonpigmented secretory epithelium of the ciliary body of eyes with end-stage POAG, whereas COX-1 expression was unchanged. By immunohistochemistry, in the ciliary bodies of eyes in five patients with diagnosis of early POAG, eyes in two had complete loss of COX-2 expression and in three showed only a few remaining scattered COX-2-expressing cells. COX-2 expression in the ciliary body was also lost in patients with steroid-induced glaucoma and was reduced in patients receiving topical steroid treatment. Eyes of patients with either congenital juvenile or angle-closure glaucoma showed COX-2 expression indistinguishable from control eyes. Aqueous humor of eyes with POAG contained significantly less PGE2 than control eyes.
CONCLUSIONS: Both cyclooxygenase isoforms are constitutively expressed in the normal human eye. Specific loss of COX-2 expression in the nonpigmented secretory epithelium of the ciliary body appears to be linked to the occurrence of POAG and steroid-induced glaucoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581208

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

1.  Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes.

Authors:  Alexandra Boussommier-Calleja; Jacques Bertrand; David F Woodward; C Ross Ethier; W Daniel Stamer; Darryl R Overby
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-24       Impact factor: 4.799

2.  Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure.

Authors:  P Liu; M Zhang; M Shoeb; D Hogan; Luosheng Tang; M F Syed; C Z Wang; G A Campbell; N H Ansari
Journal:  Free Radic Biol Med       Date:  2014-02-06       Impact factor: 7.376

3.  Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells.

Authors:  Susan E Yanni; Gary W McCollum; John S Penn
Journal:  Exp Eye Res       Date:  2010-04-14       Impact factor: 3.467

4.  Stimulation of prostaglandin EP2 receptors on RGC-5 cells in culture blunts the negative effect of serum withdrawal.

Authors:  Kui Dong Kang; B L S Andrade da Costa; N N Osborne
Journal:  Neurochem Res       Date:  2010-02-24       Impact factor: 3.996

5.  Comparative lipidomic analysis of inflammatory mediators in the aqueous humor and tear fluid of humans and rabbits.

Authors:  Dmitry V Chistyakov; Nadezhda V Azbukina; Alina A Astakhova; Sergei V Goriainov; Viktor V Chistyakov; Veronika V Tiulina; Viktoriia E Baksheeva; Vladislav I Kotelin; Elena V Fedoseeva; Andrey A Zamyatnin; Pavel P Philippov; Olga A Kiseleva; Alexander M Bessmertny; Ivan I Senin; Elena N Iomdina; Marina G Sergeeva; Evgeni Yu Zernii
Journal:  Metabolomics       Date:  2020-02-12       Impact factor: 4.290

6.  Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure.

Authors:  Román A Barraza; Jay W McLaren; Eric M Poeschla
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

Review 7.  Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction.

Authors:  Carol B Toris; B'Ann T Gabelt; Paul L Kaufman
Journal:  Surv Ophthalmol       Date:  2008-11       Impact factor: 6.048

Review 8.  Endocannabinoids in the retina: from marijuana to neuroprotection.

Authors:  Stephen Yazulla
Journal:  Prog Retin Eye Res       Date:  2008-08-03       Impact factor: 21.198

9.  Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells.

Authors:  Anja-Kristina Brust; Holger K Ulbrich; Gail M Seigel; Norbert Pfeiffer; Franz H Grus
Journal:  Biomark Insights       Date:  2008-07-08

10.  Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides.

Authors:  Scott D Smid
Journal:  Clin Ophthalmol       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.